

Express Mail Label No.: EV461505079US  
Date of Deposit: April 14, 2006

APR 17 2006

Attorney Docket No. 21486-021 DIV

1643

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS : Richard M. Terek  
SERIAL NUMBER : 09/819,144 EXAMINER : Hong Sang  
FILING DATE : March 27, 2001 ART UNIT : 1643  
FOR : CHONDROSARCOMA ASSOCIATED GENES

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 14, 2006  
Boston, Massachusetts

**TRANSMITTAL LETTER**


Enclosed herewith for filing in the above-identified application please find the following documents:

1. Amendment and Response (7 pgs);
6. Return Postcard

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21486-021 DIV. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

*Ingrid A. Beattie* Reg No 53097  
Ingrid A. Beattie, Reg. No. 42,306  
Attorney for Applicants  
c/o MINTZ LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel.: (617) 542 6000  
Fax: (617) 542-2241  
Customer No. 30623



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS : Richard M. Terek  
SERIAL NUMBER : 09/819,144 EXAMINER : Hong Sang  
FILING DATE : March 27, 2001 ART UNIT : 1643  
FOR : CHONDROSARCOMA ASSOCIATED GENES

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 14, 2006  
Boston, Massachusetts

**AMENDMENT AND RESPONSE**

This Response and Amendment is submitted in response to the Office Action mailed January 18, 2006 in the above-identified patent application. With no extension, these documents are due on or before April 18, 2006. Thus, Applicant believes no fees are due in connection with this filing. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayments of same, to Deposit Account No. 50-0311, reference 21486-021 DIV.

Please amend the above-identified application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** reflected in the listing of claims, which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 4 of this paper.